Ocular immunology and inflammation
Ocular immunology and inflammation
Audio Summaries
Every issue of Ocular immunology and inflammation moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from Ocular immunology and inflammation.
Late Diagnostic Revision to Tubercular Choroiditis in Patients with Recurrent APMPPE: A Retrospective Study in 28 Cases
Jun 8, 2026
The authors aimed to investigate the recurrence patterns of acute posterior multifocal placoid pigment epitheliopathy (APMPPE) and its potential misdiagnosis as ocular tuberculosis (TB). In a retrospective study of 28 cases, they found that 21.4% of patients experienced recurrent inflammation, with five cases ultimately reclassified as ocular TB based on lesion morphology and positive TB tests. The findings suggest that APMPPE may serve as an initial indicator of ocular TB, highlighting the need for thorough monitoring and TB evaluation in recurrent cases.
Acute Unilateral Iris Transillumination Following Topical Moxifloxacin: A Case Report and Anterior Segment Optical Coherence Tomography Findings
Jun 5, 2026
The authors aim to describe the optical coherence tomography (OCT) findings of the iris in a patient who developed unilateral acute iris transillumination after using topical moxifloxacin for corneal trauma. The study reveals distinct OCT patterns, including loss of the anterior iris border and changes in the stromal layer, which may assist in diagnosing this condition and highlight similarities with a related phenotype.
Effect of Anti-Tubercular Therapy Duration (6 Months versus ≥9-Months) on Treatment Outcomes in Serpiginous-Like Choroiditis: A Multicenter Retrospective Observational Study
Jun 5, 2026
This study aimed to determine the impact of the duration of anti-tubercular therapy (ATT) on treatment outcomes in patients with Serpiginous-Like Choroiditis, comparing 6 months versus 9 months or more of treatment. The findings revealed no significant differences in recurrence rates, persistence of inflammation, or changes in visual acuity between the two treatment durations. Additionally, the study noted instances of systemic toxicity and ethambutol-induced optic neuropathy, but these did not correlate with the duration of ATT.